2025
Same‐Day Discharge After Catheter Ablation of Atrial Fibrillation in the United States
Sandhu A, Qin L, Minges K, Zimmerman S, Borne R, Polsinelli V, Ho P, Hsu J, Al‐Khatib S, Freeman J, Bradley S, Rao S, Hernandez A, Tzou W, Varosy P, Hess P. Same‐Day Discharge After Catheter Ablation of Atrial Fibrillation in the United States. Journal Of The American Heart Association 2025, 14: e039190. PMID: 40240938, PMCID: PMC12184264, DOI: 10.1161/jaha.124.039190.Peer-Reviewed Original ResearchConceptsSame-day dischargeRate of same-day dischargeAF ablationComplication rateAtrial fibrillationPersistent AFCatheter ablation of atrial fibrillationAblation of atrial fibrillationOvernight hospitalizationLikelihood of same-day dischargeSame-day discharge ratePostprocedural complication rateSame-day discharge patientsSubstantial hospital variationCatheter ablationDays postprocedureClinical factorsBlack raceIndex procedureComorbid conditionsPatientsHospital variationSame-dayHospitalComplications
2024
A Novel Sirolimus-Coated Balloon for the Treatment of Femoropopliteal Lesions The SELUTION SFA Japan Trial
Iida O, Soga Y, Saito S, Mano T, Hayakawa N, Ichihashi S, Kawasaki D, Suzuki K, Yamaoka T, Fujihara M, Nakama T, Nakamura M, Horie K, Shah T, Lansky A, Kozuki A. A Novel Sirolimus-Coated Balloon for the Treatment of Femoropopliteal Lesions The SELUTION SFA Japan Trial. JACC Cardiovascular Interventions 2024, 17: 1547-1556. PMID: 38842992, DOI: 10.1016/j.jcin.2024.03.029.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAngioplasty, BalloonCardiovascular AgentsCoated Materials, BiocompatibleEquipment DesignFemaleFemoral ArteryHumansJapanMaleMiddle AgedPeripheral Arterial DiseasePopliteal ArteryProspective StudiesRecurrenceRisk FactorsSirolimusTime FactorsTreatment OutcomeVascular Access DevicesVascular PatencyConceptsSirolimus-coated balloonFP diseaseTreatment optionsJapan trialPrespecified performance goalTreatment of femoropopliteal lesionsClinical events committeePrimary patency rateImaging core laboratoryPeak systolic velocity ratioEffective treatment optionSingle-arm studyAdverse event ratesTarget lesion revascularizationSystolic velocity ratioAnkle-brachial index dataChronic total occlusionPrimary endpointPrimary patencySymptomatic patientsEvents committeeDays postprocedureCD-TLRDuplex ultrasoundFemoropopliteal lesions
2022
Establishment of a Percutaneous Nephrostomy Service to Treat Obstructive Uropathy Secondary to Cervical Cancer in Tanzania
Rukundo I, Mbuguje E, Naif A, Patel M, Laage-Gaupp F, Asch M, Ramalingam V. Establishment of a Percutaneous Nephrostomy Service to Treat Obstructive Uropathy Secondary to Cervical Cancer in Tanzania. The Arab Journal Of Interventional Radiology 2022, 06: 033-036. DOI: 10.1055/s-0042-1744507.Peer-Reviewed Original ResearchLate-stage cervical cancerCervical cancerDays postprocedureNephrostomy placementOcean Road Cancer InstituteTechnical success rateCervical cancer mortalityMuhimbili National HospitalPercutaneous nephrostomy placementBackground Cervical cancerResource-limited countriesLate-stage cancerResearch Electronic Data CaptureResource-limited settingsQuaternary hospitalChemoradiation therapyObstructive uropathyClinical benefitDays postinterventionPercutaneous nephrostomyRetrospective studyBenefits patientsCancer mortalityNational HospitalCommon cancer
2015
Patient-Centered Outcomes Following Thoracentesis
Argento AC, Murphy TE, Pisani MA, Araujo KL, Puchalski J. Patient-Centered Outcomes Following Thoracentesis. PLEURA 2015, 2: 237399751560040. PMID: 26767192, PMCID: PMC4708257, DOI: 10.1177/2373997515600404.Peer-Reviewed Original ResearchPleural interventionsSustained improvementPleural effusionProspective observational cohort studyTertiary care academic medical centerAdditional pleural proceduresObservational cohort studyMajority of patientsShort Form-12Multivariable logistic regressionPatient-centered outcomesAcademic medical centerSignificant clinical impactAdult patientsCohort studyHepatic hydrothoraxSecondary outcomesDays postprocedureInfectious etiologyPrimary outcomeTherapeutic thoracentesisAnalytical cohortForm-12Significant morbidityIndex procedure
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply